Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Improvements in rare cell isolation and common blood tests

Improvements in rare cell isolation and common blood tests

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Pleiotrophin protein may be long-sought growth factor for blood stem cells

Pleiotrophin protein may be long-sought growth factor for blood stem cells

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Sickle cell disease treatments: An interview with Dr Niihara, CEO of Emmaus Medical

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Maryland scientists create stem cell model for Gaucher disease

Maryland scientists create stem cell model for Gaucher disease

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

USPTO grants five-year extension to Spectrum's FOLOTYN patent

USPTO grants five-year extension to Spectrum's FOLOTYN patent

New light into evolution of human physiology and brain development

New light into evolution of human physiology and brain development

New nanodevice lays foundations for future development of novel therapies against aging

New nanodevice lays foundations for future development of novel therapies against aging

Anemia now confirmed as risk factor for illness and even death following cardiac surgery

Anemia now confirmed as risk factor for illness and even death following cardiac surgery

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Increasing doses of radium chloride effective, tolerated in prostate cancer

Increasing doses of radium chloride effective, tolerated in prostate cancer

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.